infocusaug25

The FDA has lifted REMS requirements for all approved CAR-T therapies, a move that could transform access for patients and research sites alike. What does this mean for trial participation, site activation, and the future of cell and gene therapy? Read on to see how this shift reshapes the CAR-T landscape.

Data entry continues to be one of the biggest sources of burden for sites. Electronic Health Record (EHR) to Electronic Data Capture (EDC) data transfer technology is a leading example of how sponsors, sites, and vendors are collaborating as an ecosystem to reduce the data entry bottleneck in clinical trial operations.

Improving the patient experience in clinical trials starts with supporting sites. Learn why Sponsors must prioritize the site experience to deliver better outcomes for patients and better results for the study.